The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 22, Issue 1, Pages T1-T17
Publisher
Bioscientifica
Online
2014-03-22
DOI
10.1530/erc-14-0005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance
- (2013) Z. Tian et al. BLOOD
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells
- (2013) Fabio Petrocca et al. CANCER CELL
- U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma
- (2013) T. M. Herndon et al. CLINICAL CANCER RESEARCH
- Targeting the ubiquitin–proteasome system for cancer therapy
- (2013) Min Shen et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- Targeting p53 by small molecules in hematological malignancies
- (2013) Manujendra N Saha et al. Journal of Hematology & Oncology
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
- (2013) Meletios Dimopoulos et al. LANCET ONCOLOGY
- The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4
- (2012) Yan Zang et al. Autophagy
- Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma
- (2012) Bo Hui et al. CANCER
- A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
- (2012) Dharminder Chauhan et al. CANCER CELL
- Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy
- (2012) Y. Zang et al. CLINICAL CANCER RESEARCH
- The immunoproteasome in antigen processing and other immunological functions
- (2012) Michael Basler et al. CURRENT OPINION IN IMMUNOLOGY
- Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
- (2012) Jill Gilbert et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens
- (2012) Gabriella Parma et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase I Trial Using the Proteasome Inhibitor Bortezomib and Concurrent Chemoradiotherapy for Head-and-Neck Malignancies
- (2012) Gregory J. Kubicek et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells
- (2012) Laura Gatti et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance
- (2012) Andrew J. Kale et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
- (2012) Bilal Piperdi et al. Journal of Thoracic Oncology
- Targeting the Ubiquitin+Proteasome System in Solid Tumors
- (2012) James J. Driscoll et al. SEMINARS IN HEMATOLOGY
- Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade
- (2011) Andrew S. Kraft et al. CANCER BIOLOGY & THERAPY
- Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341
- (2011) Yong Fang et al. CANCER INVESTIGATION
- Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation
- (2011) Changyou Li et al. CANCER LETTERS
- Inhibition of NEDD8-Activating Enzyme Induces Rereplication and Apoptosis in Human Tumor Cells Consistent with Deregulating CDT1 Turnover
- (2011) M. A. Milhollen et al. CANCER RESEARCH
- Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
- (2011) A. Argiris et al. CLINICAL CANCER RESEARCH
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
- (2011) Dharminder Chauhan et al. CLINICAL CANCER RESEARCH
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial
- (2011) Primo N. Lara et al. Clinical Lung Cancer
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
- (2011) D. Chen et al. CURRENT CANCER DRUG TARGETS
- Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
- (2011) Anil K. Chaturvedi et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003)
- (2011) Suresh S. Ramalingam et al. Journal of Thoracic Oncology
- Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer
- (2011) Benjamin Besse et al. LUNG CANCER
- Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo
- (2011) G. Dasmahapatra et al. MOLECULAR CANCER THERAPEUTICS
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Deubiquitinases in cancer: new functions and therapeutic options
- (2011) J M Fraile et al. ONCOGENE
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
- (2010) D. Chauhan et al. BLOOD
- The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
- (2010) G. Dasmahapatra et al. BLOOD
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer
- (2010) William J. Irvin et al. Clinical Breast Cancer
- The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
- (2010) Di Chen et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- Phase I Trial of Bortezomib and Concurrent External Beam Radiation in Patients With Advanced Solid Malignancies
- (2010) Thomas J. Pugh et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma
- (2010) George P. Kim et al. INVESTIGATIONAL NEW DRUGS
- A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
- (2010) Manish A. Shah et al. INVESTIGATIONAL NEW DRUGS
- Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)
- (2010) Angela M. Davies et al. Journal of Thoracic Oncology
- Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies
- (2010) Guido Cavaletti et al. LEUKEMIA & LYMPHOMA
- PS-341 and Histone Deacetylase Inhibitor Synergistically Induce Apoptosis in Head and Neck Squamous Cell Carcinoma Cells
- (2010) J. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Bortezomib Sensitizes Human Esophageal Squamous Cell Carcinoma Cells to TRAIL-Mediated Apoptosis via Activation of Both Extrinsic and Intrinsic Apoptosis Pathways
- (2010) N. Seki et al. MOLECULAR CANCER THERAPEUTICS
- Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
- (2010) James E. Brownell et al. MOLECULAR CELL
- Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis
- (2010) Yoshiba ONCOLOGY REPORTS
- The 26S proteasome: assembly and function of a destructive machine
- (2010) Nerea Gallastegui et al. TRENDS IN BIOCHEMICAL SCIENCES
- Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
- (2009) C. H. Chung et al. ANNALS OF ONCOLOGY
- Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
- (2009) A Z Dudek et al. BRITISH JOURNAL OF CANCER
- Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma
- (2009) Rakesh Popat et al. BRITISH JOURNAL OF HAEMATOLOGY
- Regulation of cullin-RING E3 ubiquitin-ligases by neddylation and dimerization
- (2009) J. Merlet et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment
- (2009) Z. Lin et al. CLINICAL CANCER RESEARCH
- A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
- (2009) O. A. O'Connor et al. CLINICAL CANCER RESEARCH
- Bortezomib induces autophagic death in proliferating human endothelial cells
- (2009) Daniela Belloni et al. EXPERIMENTAL CELL RESEARCH
- Clinical development of novel proteasome inhibitors for cancer treatment
- (2009) Huanjie Yang et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
- (2009) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma?
- (2009) Anders Näsman et al. INTERNATIONAL JOURNAL OF CANCER
- Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway
- (2009) Kuen-Feng Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
- (2009) Han-Jie Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
- (2009) James A Bonner et al. LANCET ONCOLOGY
- Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients
- (2009) Alessandro Corso et al. LEUKEMIA RESEARCH
- Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)
- (2009) Tianhong Li et al. LUNG CANCER
- Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models
- (2009) T. M. Pitts et al. MOLECULAR CANCER THERAPEUTICS
- Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy
- (2009) W.-X. Ding et al. MOLECULAR CANCER THERAPEUTICS
- Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death
- (2009) C. Li et al. MOLECULAR CANCER THERAPEUTICS
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- Inverse Relationship between Human Papillomavirus-16 Infection and Disruptive p53 Gene Mutations in Squamous Cell Carcinoma of the Head and Neck
- (2008) W. H. Westra et al. CLINICAL CANCER RESEARCH
- Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor
- (2008) M. Bazzaro et al. CLINICAL CANCER RESEARCH
- Bortezomib-Induced Apoptosis with Limited Clinical Response Is Accompanied by Inhibition of Canonical but not Alternative Nuclear Factor- B Subunits in Head and Neck Cancer
- (2008) C. Allen et al. CLINICAL CANCER RESEARCH
- Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma
- (2008) Donna E. Reece et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study
- (2008) Peter S. Kozuch et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States
- (2008) Anil K. Chaturvedi et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer
- (2008) Bruce D. Dorsey et al. JOURNAL OF MEDICINAL CHEMISTRY
- Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody
- (2008) A. Shanker et al. JNCI-Journal of the National Cancer Institute
- BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells
- (2008) P Pérez-Galán et al. LEUKEMIA
- The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
- (2008) E Terpos et al. LEUKEMIA
- Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells
- (2008) Changyou Li et al. MOLECULAR CANCER THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started